Maladaptive positive feedback production of ChREBPβ underlies glucotoxic β-cell failure.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
30 07 2022
Historique:
received: 16 12 2021
accepted: 18 07 2022
entrez: 30 7 2022
pubmed: 31 7 2022
medline: 3 8 2022
Statut: epublish

Résumé

Preservation and expansion of β-cell mass is a therapeutic goal for diabetes. Here we show that the hyperactive isoform of carbohydrate response-element binding protein (ChREBPβ) is a nuclear effector of hyperglycemic stress occurring in β-cells in response to prolonged glucose exposure, high-fat diet, and diabetes. We show that transient positive feedback induction of ChREBPβ is necessary for adaptive β-cell expansion in response to metabolic challenges. Conversely, chronic excessive β-cell-specific overexpression of ChREBPβ results in loss of β-cell identity, apoptosis, loss of β-cell mass, and diabetes. Furthermore, β-cell "glucolipotoxicity" can be prevented by deletion of ChREBPβ. Moreover, ChREBPβ-mediated cell death is mitigated by overexpression of the alternate CHREBP gene product, ChREBPα, or by activation of the antioxidant Nrf2 pathway in rodent and human β-cells. We conclude that ChREBPβ, whether adaptive or maladaptive, is an important determinant of β-cell fate and a potential target for the preservation of β-cell mass in diabetes.

Identifiants

pubmed: 35908073
doi: 10.1038/s41467-022-32162-x
pii: 10.1038/s41467-022-32162-x
pmc: PMC9339008
doi:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
Nuclear Proteins 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

4423

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK124461
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121140
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK116873
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK100425
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007792
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121844
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108905
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK105015
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114338
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS097184
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI093637
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK129196
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK130300
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020541
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK126450
Pays : United States
Organisme : NIH HHS
ID : OT2 OD024912
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK125285
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Wang, P. et al. Diabetes mellitus-advances and challenges in human beta-cell proliferation. Nat. Rev. Endocrinol. 11, 201–212 (2015).
pubmed: 25687999 doi: 10.1038/nrendo.2015.9
Wang, P. et al. Human beta cell regenerative drug therapy for diabetes: past achievements and future challenges. Front. Endocrinol. 12, 671946 (2021).
doi: 10.3389/fendo.2021.671946
Porat, S. et al. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab. 13, 440–449 (2011).
pubmed: 21459328 doi: 10.1016/j.cmet.2011.02.012
Robertson, R. P., Harmon, J., Tran, P. O. & Poitout, V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53, S119–S124 (2004).
pubmed: 14749276 doi: 10.2337/diabetes.53.2007.S119
Metukuri, M. R. et al. ChREBP mediates glucose-stimulated pancreatic beta-cell proliferation. Diabetes 61, 2004–2015 (2012).
pubmed: 22586588 pmcid: 3402328 doi: 10.2337/db11-0802
Yamashita, H. et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl Acad. Sci. USA 98, 9116–9121 (2001).
pubmed: 11470916 pmcid: 55382 doi: 10.1073/pnas.161284298
Shalev, A. Minireview: Thioredoxin-interacting protein: regulation and function in the pancreatic β-cell. Mol. Endocrinol. 28, 1211–1220 (2014).
pubmed: 24911120 pmcid: 4116588 doi: 10.1210/me.2014-1095
Kumar, A. et al. Activation of Nrf2 is required for normal and ChREBPalpha-augmented glucose-stimulated beta-cell proliferation. Diabetes 67, 1561–1575 (2018).
pubmed: 29764859 pmcid: 6054434 doi: 10.2337/db17-0943
Herman, M. A. & Kahn, B. B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Investig. 116, 1767–1775 (2006).
pubmed: 16823474 pmcid: 1483149 doi: 10.1172/JCI29027
Zhang, P. et al. Induction of the ChREBPbeta isoform is essential for glucose-stimulated beta cell proliferation. Diabetes 64, 4158–4170 (2015).
pubmed: 26384380 pmcid: 4657577 doi: 10.2337/db15-0239
Herman, M. A. et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484, 333–338 (2012).
pubmed: 22466288 pmcid: 3341994 doi: 10.1038/nature10986
Sae-Lee, C., Moolsuwan, K., Chan, L. & Poungvarin, N. ChREBP regulates itself and metabolic genes implicated in lipid accumulation in β-cell line. PLoS ONE 11, e0147411 (2016).
pubmed: 26808438 pmcid: 4725739 doi: 10.1371/journal.pone.0147411
Jing, G., Chen, J., Xu, G. & Shalev, A. Islet ChREBP-beta is increased in diabetes and controls ChREBP-alpha and glucose-induced gene expression via a negative feedback loop. Mol. Metab. 5, 1208–1215 (2016).
pubmed: 27900263 pmcid: 5123192 doi: 10.1016/j.molmet.2016.09.010
Poungvarin, N. et al. Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity. Diabetologia 55, 1783–1796 (2012).
pubmed: 22382520 pmcid: 4010252 doi: 10.1007/s00125-012-2506-4
Baumel-Alterzon, S. et al. Nrf2 Regulates β-Cell Mass by Suppressing β-Cell Death and Promoting β-Cell Proliferation. Diabetes 71, 989–1011 (2022).
Cha-Molstad, H., Saxena, G., Chen, J. & Shalev, A. Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells. J. Biol. Chem. 284, 16898–16905 (2009).
pubmed: 19411249 pmcid: 2719326 doi: 10.1074/jbc.M109.010504
Davies, M. N., O’Callaghan, B. L. & Towle, H. C. Glucose activates ChREBP by increasing its rate of nuclear entry and relieving repression of its transcriptional activity. J. Biol. Chem. 283, 24029–24038 (2008).
pubmed: 18591247 pmcid: 2527113 doi: 10.1074/jbc.M801539200
Noordeen, N. A., Meur, G., Rutter, G. A. & Leclerc, I. Glucose-induced nuclear shuttling of ChREBP is mediated by sorcin and Ca(2+) ions in pancreatic beta-cells. Diabetes 61, 574–585 (2012).
pubmed: 22338092 pmcid: 3282809 doi: 10.2337/db10-1329
Abdul-Wahed, A., Guilmeau, S. & Postic, C. Sweet sixteenth for ChREBP: established roles and future goals. Cell Metab. 26, 324–341 (2017).
pubmed: 28768172 doi: 10.1016/j.cmet.2017.07.004
Stoeckman, A. K., Ma, L. & Towle, H. C. Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes. J. Biol. Chem. 279, 15662–15669 (2004).
pubmed: 14742444 doi: 10.1074/jbc.M311301200
Zhang, P. et al. c-Myc is required for the CHREBP-dependent activation of glucose-responsive genes. Mol. Endocrinol. 24, 1274–1286 (2010).
pubmed: 20382893 pmcid: 2875801 doi: 10.1210/me.2009-0437
Wang, H. et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. Nat. Commun. 8, 767 (2017).
pubmed: 28974674 pmcid: 5626682 doi: 10.1038/s41467-017-00992-9
Gómez-Banoy, N. et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat. Med. 25, 1739–1747 (2019).
pubmed: 31700183 pmcid: 7256970 doi: 10.1038/s41591-019-0610-4
Wang, P. et al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat. Med. 21, 383–388 (2015).
pubmed: 25751815 pmcid: 4690535 doi: 10.1038/nm.3820
Wicksteed, B. et al. Conditional gene targeting in mouse pancreatic ss-Cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 59, 3090–3098 (2010).
pubmed: 20802254 pmcid: 2992770 doi: 10.2337/db10-0624
Herrera, P. L., Orci, L. & Vassalli, J. D. Two transgenic approaches to define the cell lineages in endocrine pancreas development. Mol. Cell. Endocrinol. 140, 45–50 (1998).
pubmed: 9722167 doi: 10.1016/S0303-7207(98)00028-8
Collier, J. J. et al. c-Myc and ChREBP regulate glucose-mediated expression of the L-type pyruvate kinase gene in INS-1-derived 832/13 cells. Am. J. Physiol. Endocrinol. Metab. 293, E48–E56 (2007).
pubmed: 17341548 doi: 10.1152/ajpendo.00357.2006
Rosselot, C. et al. Myc is required for adaptive beta-cell replication in young mice but is not sufficient in one-year-old mice fed with a high-fat diet. Diabetes 68, 1934–1949 (2019).
pubmed: 31292135 pmcid: 6754239 doi: 10.2337/db18-1368
Brionne, A., Juanchich, A. & Hennequet-Antier, C. ViSEAGO: a Bioconductor package for clustering biological functions using Gene Ontology and semantic similarity. BioData Min. 12, 16 (2019).
pubmed: 31406507 pmcid: 6685253 doi: 10.1186/s13040-019-0204-1
Chen, J., Saxena, G., Mungrue, I. N., Lusis, A. J. & Shalev, A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 57, 938–944 (2008).
pubmed: 18171713 doi: 10.2337/db07-0715
Nie, Z. et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68–79 (2012).
pubmed: 23021216 pmcid: 3471363 doi: 10.1016/j.cell.2012.08.033
Puri, S. et al. Replication confers beta cell immaturity. Nat. Commun. 9, 485 (2018).
pubmed: 29396395 pmcid: 5797102 doi: 10.1038/s41467-018-02939-0
Sharma, R. B., Darko, C., Zheng, X., Gablaski, B. & Alonso, L. C. DNA damage does not cause BrdU labeling of mouse or human β-cells. Diabetes 68, 975–987 (2019).
pubmed: 30833468 pmcid: 6477907 doi: 10.2337/db18-0761
Rieck, S. & Kaestner, K. H. Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol. Metab. 21, 151–158 (2010).
pubmed: 20015659 doi: 10.1016/j.tem.2009.11.001
Robertson, R. P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 279, 42351–42354 (2004).
pubmed: 15258147 doi: 10.1074/jbc.R400019200
Weir, G.C., Butler, P.C. & Bonner-Weir, S. The β-cell glucose toxicity hypothesis: attractive but difficult to prove. Metabolism 124, 154870 (2021).
Park, M. J. et al. High glucose-induced O-GlcNAcylated carbohydrate response element-binding protein (ChREBP) mediates mesangial cell lipogenesis and fibrosis: the possible role in the development of diabetic nephropathy. J. Biol. Chem. 289, 13519–13530 (2014).
pubmed: 24616092 pmcid: 4036358 doi: 10.1074/jbc.M113.530139
Agius, L., Chachra, S. S. & Ford, B. E. The protective role of the carbohydrate response element binding protein in the liver: the metabolite perspective. Front Endocrinol. (Lausanne) 11, 594041 (2020).
doi: 10.3389/fendo.2020.594041
Katz, L. S., Baumel-Alterzon, S., Scott, D. K. & Herman, M. A. Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets. J. Biol. Chem. 296, 100623 (2021).
pubmed: 33812993 pmcid: 8102921 doi: 10.1016/j.jbc.2021.100623
Bricambert, J. et al. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. Nat. Commun. 9, 2092 (2018).
pubmed: 29844386 pmcid: 5974278 doi: 10.1038/s41467-018-04361-y
Lane, E. A. et al. HCF-1 regulates de novo lipogenesis through a nutrient-sensitive complex with ChREBP. Mol. Cell 75, 357–371.e357 (2019).
pubmed: 31227231 pmcid: 6744259 doi: 10.1016/j.molcel.2019.05.019
Bahar Halpern, K. et al. Nuclear retention of mRNA in mammalian tissues. Cell Rep. 13, 2653–2662 (2015).
pubmed: 26711333 pmcid: 4700052 doi: 10.1016/j.celrep.2015.11.036
Mejhert, N. et al. Partitioning of MLX-family transcription factors to lipid droplets regulates metabolic gene expression. Mol. Cell 77, 1251–1264.e1259 (2020).
pubmed: 32023484 pmcid: 7397554 doi: 10.1016/j.molcel.2020.01.014
Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. & Uyeda, K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl Acad. Sci. USA 101, 7281–7286 (2004).
pubmed: 15118080 pmcid: 409910 doi: 10.1073/pnas.0401516101
Shimabukuro, M., Zhou, Y. T., Levi, M. & Unger, R. H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc. Natl Acad. Sci. USA 95, 2498–2502 (1998).
pubmed: 9482914 pmcid: 19389 doi: 10.1073/pnas.95.5.2498
Gonzalez-Pertusa, J. A. et al. Novel proapoptotic effect of hepatocyte growth factor: synergy with palmitate to cause pancreatic {beta}-cell apoptosis. Endocrinology 151, 1487–1498 (2010).
pubmed: 20176723 pmcid: 2850223 doi: 10.1210/en.2009-0975
Shalev, A. Lack of TXNIP protects beta-cells against glucotoxicity. Biochemical Soc. Trans. 36, 963–965 (2008).
doi: 10.1042/BST0360963
Lei, Y., Zhou, S., Hu, Q., Chen, X. & Gu, J. Carbohydrate response element binding protein (ChREBP) correlates with colon cancer progression and contributes to cell proliferation. Sci. Rep. 10, 4233 (2020).
pubmed: 32144313 pmcid: 7060312 doi: 10.1038/s41598-020-60903-9
Laybutt, D. R. et al. Overexpression of c-Myc in beta-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. Diabetes 51, 1793–1804 (2002).
pubmed: 12031967 doi: 10.2337/diabetes.51.6.1793
Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012).
pubmed: 23021215 pmcid: 3462372 doi: 10.1016/j.cell.2012.08.026
da Silva Xavier, G., Sun, G., Qian, Q., Rutter, G. A. & Leclerc, I. ChREBP regulates Pdx-1 and other glucose-sensitive genes in pancreatic β-cells. Biochem. Biophys. Res. Commun. 402, 252–257 (2010).
pubmed: 20934404 pmcid: 2989445 doi: 10.1016/j.bbrc.2010.10.010
Jurczak, M. J. et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60, 890–898 (2011).
pubmed: 21357472 pmcid: 3046850 doi: 10.2337/db10-1328
Kjørholt, C., Akerfeldt, M. C., Biden, T. J. & Laybutt, D. R. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 54, 2755–2763 (2005).
pubmed: 16123366 doi: 10.2337/diabetes.54.9.2755
Wang, Z., York, N. W., Nichols, C. G. & Remedi, M. S. Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 19, 872–882 (2014).
pubmed: 24746806 pmcid: 4067979 doi: 10.1016/j.cmet.2014.03.010
de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
pubmed: 24206459 pmcid: 4496027 doi: 10.1056/NEJMoa1306033
Toto, R. D. Bardoxolone-the Phoenix? J. Am. Soc. Nephrology 29, 360–361 (2018).
doi: 10.1681/ASN.2017121317
Baumel-Alterzon, S., Katz, L.S., Brill, G., Garcia-Ocaña, A. & Scott, D. K. Nrf2: The master and captain of beta cell fate. Trends Endocrinol. Metab. 32, 7–19 (2020).
Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296–300 (2010).
pubmed: 20075245 doi: 10.1126/science.1184003
Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223–1234 (2012).
pubmed: 22980982 pmcid: 3445031 doi: 10.1016/j.cell.2012.07.029
Wali, J. A. et al. The proapoptotic BH3-only proteins Bim and Puma are downstream of endoplasmic reticulum and mitochondrial oxidative stress in pancreatic islets in response to glucotoxicity. Cell Death Dis. 5, e1124 (2014).
pubmed: 24625983 pmcid: 3973197 doi: 10.1038/cddis.2014.88
Wang, H., Kouri, G. & Wollheim, C. B. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J. Cell Sci. 118, 3905–3915 (2005).
pubmed: 16091421 doi: 10.1242/jcs.02513
Hohmeier, H. E. et al. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49, 424–430 (2000).
pubmed: 10868964 doi: 10.2337/diabetes.49.3.424
Ricordi, C. & Rastellini, C. In: Methods in Cell Transplantation (ed. Ricordi, C.). (R. G. Landes, 1995).
Garcia-Ocana, A. et al. Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcomes in mice. Diabetes 50, 2752–2762 (2001).
pubmed: 11723058 doi: 10.2337/diabetes.50.12.2752
Becker, T. C. et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43, 161–189 (1994).
pubmed: 7823861 doi: 10.1016/S0091-679X(08)60603-2
Wang, P. et al. Combined inhibition of DYRK1A, SMAD, and trithorax pathways synergizes to induce robust replication in adult human beta cells. Cell Metab. 29, 638–652.e635 (2019).
pubmed: 30581122 doi: 10.1016/j.cmet.2018.12.005
Madisen, L. et al. Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron 85, 942–958 (2015).
pubmed: 25741722 pmcid: 4365051 doi: 10.1016/j.neuron.2015.02.022
Estall, J. L. & Screaton, R. A. Of mice and men, redux: modern challenges in β cell gene targeting. Endocrinology 161, bqaa078 (2020).
Ackeifi, C. et al. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration. Sci. Transl. Med. 12, eaaw9996 (2020).
Lakshmipathi, J. et al. PKC-zeta is essential for pancreatic beta cell replication during insulin resistance by regulating mTOR and cyclin-D2. Diabetes 65, 1283–1296 (2016).
Alvarsson, A. et al. A 3D atlas of the dynamic and regional variation of pancreatic innervation in diabetes. Sci. Adv. 6, eaaz9124 (2020).
Davenport, B. et al. Aging of antiviral CD8(+) memory T cells fosters increased survival, metabolic adaptations, and lymphoid tissue homing. J. Immunol. 202, 460–475 (2019).
pubmed: 30552164 doi: 10.4049/jimmunol.1801277
Katz, L. S., Xu, S., Ge, K., Scott, D. K. & Gershengorn, M. C. T3 and glucose coordinately stimulate ChREBP-mediated Ucp1 expression in brown adipocytes from male mice. Endocrinology 159, 557–569 (2018).
pubmed: 29077876 doi: 10.1210/en.2017-00579

Auteurs

Liora S Katz (LS)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Gabriel Brill (G)

Pharmacologic Sciences Department, Stony Brook University, Stony Brook, NY, USA.

Pili Zhang (P)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Anil Kumar (A)

Metabolic Phenotyping Core, University of Utah, 15N 2030 E, 585, Radiobiology building, Room 151, Salt Lake City, UT, 84112, USA.

Sharon Baumel-Alterzon (S)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Lee B Honig (LB)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Nicolás Gómez-Banoy (N)

Weill Center for Metabolic Health and Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.

Esra Karakose (E)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Marius Tanase (M)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Ludivine Doridot (L)

Institut Cochin, Université de Paris, INSERM, CNRS, F-75014, Paris, France.

Alexandra Alvarsson (A)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.
Alpenglow Biosciences, Inc., 98103, Seattle, WA, USA.

Bennett Davenport (B)

12800 East 19th Ave, Anschutz Medical Campus, Room P18-9403, University of Colorado, Aurora, CO, 80045, USA.

Peng Wang (P)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Luca Lambertini (L)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Sarah A Stanley (SA)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Dirk Homann (D)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Andrew F Stewart (AF)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

James C Lo (JC)

Weill Center for Metabolic Health and Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.

Mark A Herman (MA)

Division of Endocrinology and Metabolism and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA.
Section of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, One Baylor Plaza, MS: 185, R614, 77030, Houston, TX, USA.

Adolfo Garcia-Ocaña (A)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA.

Donald K Scott (DK)

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1152, New York, 10029, USA. donald.scott@mssm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH